ImmuCell (ICCC) and Its Competitors Critical Comparison

ImmuCell (NASDAQ: ICCC) is one of 25 public companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare ImmuCell to related businesses based on the strength of its profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ImmuCell and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmuCell 0 0 1 0 3.00
ImmuCell Competitors 321 831 1039 96 2.40

ImmuCell currently has a consensus price target of $14.00, indicating a potential upside of 181.12%. As a group, “Diagnostic substances” companies have a potential downside of 4.84%. Given ImmuCell’s stronger consensus rating and higher probable upside, equities analysts clearly believe ImmuCell is more favorable than its competitors.

Risk & Volatility

ImmuCell has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, ImmuCell’s competitors have a beta of 1.77, indicating that their average stock price is 77% more volatile than the S&P 500.

Profitability

This table compares ImmuCell and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ImmuCell -10.98% -5.35% -3.98%
ImmuCell Competitors -1,029.72% -22.21% -26.41%

Earnings and Valuation

This table compares ImmuCell and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ImmuCell $13.72 million -$1.30 million -26.21
ImmuCell Competitors $408.45 million -$6.78 million 119.28

ImmuCell’s competitors have higher revenue, but lower earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

14.0% of ImmuCell shares are owned by institutional investors. Comparatively, 54.6% of shares of all “Diagnostic substances” companies are owned by institutional investors. 13.9% of ImmuCell shares are owned by insiders. Comparatively, 8.1% of shares of all “Diagnostic substances” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

ImmuCell beats its competitors on 8 of the 13 factors compared.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.